Experience

Aronora, Inc.

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• President & CEO

  • Nov 2021 - Present

• Co-Founder & COO

  • Sep 2009 - Nov 2021

  Aronora is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines for hematologic diseases with significant unmet medical need. We have a talented and dedicated team of scientists and clinicians with extensive experience in pharmaceutical development, from product discovery through commercialization. Our robust pipeline of innovative product candidates target disease modifying pathways with unique mechanisms of action. We aim to quickly bring these exciting new therapies to patients in need.Aronora is focused on building a portfolio of safe drug products for a variety of clinical indications. Aronora’s business strategy is to build value in our product candidates by validating our disease modifying concepts through proof-of-concept clinical studies. We welcome qualified investment, strategic partnerships, and out-licensing opportunities that are consistent with our business strategy and company mission. Show less



OHSU | Oregon Health & Science University

• Research Assistant Professor

  • Jan 2014 - Present

  The purpose of my academic research is to explore and elucidate the molecular nature of blood coagulation, with the goal of effectively translating this fundamental knowledge into the development of new and safer antithrombotic treatments. My research continues this exploration into the elemental aspects of thrombosis and hemostasis with the ultimate goal of creating safe molecular-targeted therapies for treating major thrombotic diseases, including heart attack, stroke, and sepsis. The purpose of my academic research is to explore and elucidate the molecular nature of blood coagulation, with the goal of effectively translating this fundamental knowledge into the development of new and safer antithrombotic treatments. My research continues this exploration into the elemental aspects of thrombosis and hemostasis with the ultimate goal of creating safe molecular-targeted therapies for treating major thrombotic diseases, including heart attack, stroke, and sepsis.